Mar 04, 2010 (Datamonitor via COMTEX) — France-based biopharmaceutical company NicOx and Bausch & Lomb, an eye health company, have entered into a licensing agreement which grants Bausch & Lomb exclusive worldwide rights to develop and commercialize NCX 116, a nitric oxide-donating prostaglandin

Under the terms of the agreement, Bausch & Lomb will make an initial license payment to NicOx of $10 million, followed by potential development, regulatory, commercialization and sales success-based milestones, which, over time, could total $169.5 million. Read the full story at Trading Markets